AstraZeneca Tezspire, also known as tezepelumab, has received approval from the European Commission to treat adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP). For patients who have not responded well to conventional treatments like systemic corticosteroids and surgery, this ground-breaking ruling provides a new therapeutic option.
Tezspire is currently approved for use in conjunction with intranasal corticosteroids as an adjuvant treatment. For those who suffer from this difficult and frequently incapacitating condition, the approval marks a significant milestone. Persistent sinus and nasal passage inflammation, which results in the development of benign, teardrop-shaped polyps, is a characteristic of CRSwNP. Severe nasal congestion, diminished or absent smell, and facial pressure or pain are all possible side effects of these polyps.
In Europe, we know that nearly half of patients with chronic rhinosinusitis with nasal polyps remain uncontrolled despite treatment with standard of care, which is why today’s approval of Tezspire is such an important step forward in this challenging disease. This approval broadens Tezspire’s benefits beyond severe asthma and reinforces Tezspire’s innovative mechanism of action that targets thymic stromal lymphopoietin (TSLP), uniquely addressing epithelial-driven inflammation at its source.
Ruud Dobber
Read More: AstraZeneca Released Satisfactory Results of 24 Weeks CALYPSO Phase III Trial for Eneboparatide
The positive results from a clinical trial that showed Tezspire’s effectiveness in minimising nasal congestion and shrinking nasal polyps served as the basis for the approval. Additionally, it was demonstrated that the treatment significantly reduced the use of systemic corticosteroids, which can have long-term side effects, and almost completely eliminated the need for surgery.
Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN
The FDA has granted traditional approval to Novartis' Fabhalta (iptacopan) — the first complement inhibitor shown to significantly slow kidney function decline in adults with […]
Tezspire was previously approved for severe asthma, but its indications have been expanded with its approval for CRSwNP. The drug’s potential to treat a variety of inflammatory conditions is highlighted by this new application. The European Commission has now formally adopted the drug, which was previously approved by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). All member states of the European Union are covered by this approval.
Last Modified:
